anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Each of 2 MRI visits will consist of gadopiclenol injection or comparator injection and MRI procedure (administered in a randomized, blinded and cross-over design). Gadopiclenol and comparator will be injected as a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector. The injection rate should be identical for both products and may vary depending on scanned organ/region and age of patients.
A medicinal agent for inactivating proteoyltic enzymes in the treatment of peptic ulcer is prepared by combining an acid-adsorbing resin with a mono-alkyl sulphuric ester having an alkyl chain of from 6 to 30 carbon atoms.  The preferred resin is a polyamine phenol formaldehyde acid adsorbing resin (e.g. the polyethylene polyamine methylene substituted resin of diphenylol dimethyl methane and formaldehyde) in base form.  Other suitable resins are metaphenylene diamine-formaldehyde; resins prepared from amines and polysaccharides, ethanolamine alkyl resins, alkylated aromatic diamines, aromatic amines both unmodified and modified by incorporating into the resin structure during preparation alkyl groups to form quaternary ammonium bases; amine resins co-condensed with aliphatic polyamines or polyimines; amine resins treated during preparation with cyanamide or dicyandiamide; and resins prepared by reacting aliphatic polyamines with polyhalogen derivatives of hydrocarbons.  Suitable sulphuric acid esters include the dodecyl and tetradecyl mono esters of sulphuric acid.  The agent may be prepared by contacting an aqueous solution of the sodium salt of the sulphuric acid ester with a cation exchange resin (e.g. phenol-formaldehyde) and bringing the clear filtrate which now contains the mono sulphuric acid ester into contact with the acid adsorbing resin. Alternatively and preferably the aqueous solution of the alkyl sulphate is passed through a mixture of the cation exchange resin and the acid adsorbing resin, the particle size of one resin being substantially different from the particle size of the other, and the two resins being subsequently separated by screening, sedimentation or centrifuging. Preferably the particles of the acid adsorbing resin are the smaller. The agents are administered, if desired, in admixture with flavouring and colouring materials, clay, bentonite, magnesium or aluminium oxide, aluminium phosphates, basic aluminium acetates, bismuth suboxide, bismuth or zirconium subcarbonates methyl cellulose, carboxy methyl cellulose, gastric muscin, sulphated gluten, gums, muculages, gelatin, amino acids and other salts, peptones and peptides.
Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. These sessions took about 22 minutes.
Representative data set of participants from study RB-US-13-0003 or both studies RB-US-13-0003 and INDV-6000-301 who received at least 2 doses of SUBLOCADE 12-36 months prior. Part A consists of a single visit (Visit 1) for both screening and collection of blood and urine samples.
For the participants in the sham group, a device with a similar appearance will be used that did not emit radiation. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
INTRODUCTION: Systemic inflammatory response syndrome (SIRS) is one of the most serious complications in patients undergoing percutaneous nephrolithotomy (PCNL). Although glucocorticoids are increasingly used during PCNL, few studies have been concerned about the association between glucocorticoids and postoperative SIRS. The study aims to explore whether preoperative use of glucocorticoids is associated with SIRS after PCNL.
METHODS: A total of 1259 patients who underwent PCNL between January 2015 and April 2021 were enrolled in the retrospective cohort study. Risk factors for post-PCNL SIRS were identified by univariate and multivariate regression analysis. To further explore the association between preoperative administration of glucocorticoids and SIRS, 113 pairs of patients were matched for the confounding factors using propensity score matching (PSM) analysis. The odds ratios (OR) and 95 % confidence intervals (CI) for the above variables were analyzed.
RESULTS: The incidence of SIRS after PCNL was 9.6 % (121/1259) and the patients who suffered from postoperative SIRS had longer hospital stays and higher hospital costs (all p < 0.05). Multivariate logistic regression analysis indicated that female, preoperative leukocyte count, insertion of central vein catheter, serum albumin, preoperative high-sensitive C-reactive protein/albumin ratio, preoperative transfusion, preoperative administration of glucocorticoids were independent risk factors for SIRS (all p < 0.05). After minimization, the effects of confounding factors by PSM, preoperative administration of glucocorticoids was significantly correlated with SIRS in patients after PCNL (OR=2.44, 95 %CI: 1.31-4.55, p = 0.005).
CONCLUSION: Preoperative administration of glucocorticoids is an independent risk factor for SIRS in patients undergoing PCNL.
The control group will receive standard care - 3 monthly STI screening, motivational interviewing and counselling. Both groups will get questionnaires on mental health problems: ADHD, depression, anxiety disorder, alexithymia and sex and drug addiction.
FIELD: agriculture. SUBSTANCE: antiseptic agent has cationic surface-active substance N-alkyl-N-alkoxycarbonylmethylhexahydroazepinium chloride or polybenzylpyridinium chloride or didecyldimethylammonium chloride or dialkyldimethylammonium chloride or cetylpyridinium bromide or cetylpyridinium chloride or cetyltrimethylammonium bromide or cetyltrimethylammonium chloride or alkyldimethylbenzylammonium chloride or alkyloylaminopropyldimethylbenzylammonium chloride or 1,2-ethylene-bis-(N-dimethylcarbdecyloxymethyl)-ammonium dichloride or chlorohexidine or derivative of di-N-oxide of quinoxaline-dioxidine or quinoxidine as active substance. Acid: boric, lactic, tartaric, propionic, citric, glycolic, sorbic or salicylic acid. Low-molecular glycol: polypropylene glycol or propylene glycol or polyethylene glycol-400 or polyethylene glycol-300 or triethylene glycol. EFFECT: enhanced effectiveness of antiseptic agent. 4 cl
OBJECTIVE: To assess the mid-term clinical outcomes, hemodynamics, left ventricular (LV) mass regression, and structural valve deterioration (SVD) in patients implanted with the Perceval aortic sutureless valve across valve sizes.
METHODS: Data were obtained from a multicenter European trial and a US Investigational Device Exemption trial. Echocardiography data were analyzed by an echocardiography core lab. A mixed-effects regression model was used to assess relationships between hemodynamic outcomes, time from the procedure, and valve sizes. The Valve Academic Research Consortium (VARC)-3 definition for bioprosthetic valve failure was applied.
RESULTS: A Perceval sutureless valve was implanted in 970 patients. The median patient age was 77.8 years, 57.2% were female, the median Society of Thoracic Surgeons predicated risk of mortality was 3.3% (range, 2.1%-6.2%), and 33.4% had a concomitant procedure. The median clinical follow-up was 45.7 months (range, 28.2-76.1 months). Small and medium valves were implanted more commonly in women than in men (16.9% vs 1.9% for small and 55.1% vs 19.5% for medium; P < .001). The mean aortic valve gradients decreased significantly postimplantation and remained stable across all valve sizes throughout the follow-up period. All patients were free from severe patient-prosthesis mismatch (with an effective orifice area/m2 of >0.8). Significant LV mass regression was documented regardless valve sizes, plateaued at -9.1% at 5 years. Freedom from SVD and reintervention were 95.2% and 96.3%, respectively, at 5 years and were independent of implanted valve size (P = .22). The VARC-3 stage 3 bioprosthetic valve failure rate was low, 2.8% at 5 years.
CONCLUSIONS: The Perceval valve demonstrated low and stable mean gradients, significant LV mass regression, and low SVD and reintervention rates across all valve sizes.
Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons.
PURPOSE:To modify the titled substance useful as an antiviral agent, antimali- gnant-tumor agent, etc., by treating an interferon with a boron-based reducing agent, thereby changing the electrical charge, etc. without losing the activity, delaying the clearance in the living body, and increasing the drug activity. CONSTITUTION:An interferon is dissolved in a 0.1M phosphate buffer solution added with 10% glycerol, left to stand for one night under ice cooling, added with a boron-based reducing agent such as an aqueous solution of NaBH4, and left under ice cooling. After the completion of the reaction, the mixture is dialyzed with 0.1M phosphate buffer solution, etc. for one night under ice cooling. The liquid left after the dialysis is freeze-dried, and reconstituted to an aqueous solution by adding water thereto. The objective reduced interferon having modified physical properties such as electrical charge, etc. can be obtained by this process without losing the activity.
This study is being conducted to assess how a short, online educational video changes knowledge about fertility and infertility in couples attending an infertility clinic for the first time. Participants will complete a questionnaire testing knowledge about infertility and general demographic information (age, gender, previous information sources on infertility, etc.) will be collected. Participants will then be directed to a short video on infertility. One week later, participants will return to the site to complete the infertility test questions a second time in order to test memory retention. The focus of both the questionnaire and educational video will be basic reproductive biology, infertility risk factors, etiologies and treatments and fertility myths.
Patients in the acupuncture group received acupuncture therapy (snap-needle therapy) for 24 hours. Results of the study were collected at six assessment periods of 0-0.5 h, 0-1 h, 1-3 h, 4-6h, 6-12 h, and 12-24 h after anesthesia. Conducted by an independent researcher.
Shake can prior to use. Apply Halobetasol Propionate Topical Foam as a thin uniform film to the affected skin twice daily for up to two weeks. Rub in gently. Wash hands after applying the product.

Discontinue therapy when control is achieved. If no improvement is seen within two weeks, reassessment of the diagnosis may be necessary.

Treatment beyond two weeks is not recommended and the total dosage should not exceed 50 grams per week because of the potential for the drug to suppress the hypothalamic-pituitary­ adrenal (HPA) axis [see Warnings and Precautions (5.1)]. Do not use with occlusive dressings unless directed by a physician.

Avoid use on the face, groin, or axillae.

Avoid contact with eyes.

Halobetasol Propionate Topical Foam is for topical use only.

Halobetasol Propionate Topical Foam is not for ophthalmic, oral, or intravaginal use.
For patients in the control group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and placebo (normal saline). The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours.
Deterioration of neurovascular conditions can be rapid in patients with spontaneous subarachnoid haemorrhage (SAH) and often lead to poor clinical outcomes. Therefore, it is crucial to promptly assess and continually track the progression of the disease. This study incorporated baseline clinical conditions, repeatedly measured neurological grades and haematological biomarkers for dynamic outcome prediction in patients with spontaneous SAH. Neurological intervention, mainly aneurysm clipping and endovascular embolisation, was also incorporated as an intermediate event in developing a neurological intervention transition (NIT) joint model. A retrospective cohort study was performed on 701 patients in spontaneous SAH with a study period of 14 days from the MIMIC-IV dataset. A dynamic prognostic model predicting outcome of patients was developed based on combination of Cox model and piecewise linear mixed-effect models to incorporate different types of prognostic information. Clinical baseline covariates, including cerebral oedema, cerebral infarction, respiratory failure, hydrocephalus and vasospasm, as well as repeated measured Glasgow Coma Scale (GCS), glucose and white blood cell (WBC) levels were covariates contributing to the optimal model. Incorporation of neurological intervention as an intermediate event increases the prediction performance compared with baseline joint modelling approach. The average AUC of the optimal model proposed in this study is 0.7783 across different starting points of prediction and prediction intervals. The model proposed in this study can provide dynamic prognosis for spontaneous SAH patients and significant potential benefits in critical care management.
The endoplasmic reticulum (ER), the center of protein folding, also controls the cell's life-and-death signaling mechanisms. ER stress caused by unfolded or misfolded proteins leads to the activation of the unfolded protein response (UPR) in the cell. The UPR utilizes three main signaling pathways to restore disrupted ER homeostasis. These signaling pathways are protein kinase R-like endoplasmic reticulum kinase, inositol-requiring enzyme 1, and activating transcription factor 6. Studies have reported that ER stress (ERS) plays a role in the pathogenesis of metabolic disorders such as diabetes, obesity, atherosclerosis, and nonalcoholic liver disease. This review will briefly discuss the ERS response in these metabolic diseases.
Following screening and consenting processes, patients will be randomized to enroll in interventional or control groups. The interventional group will listen to an audio recording of psychological support based on positive suggestion for about 30 min each day via headphones. At the time of ICU discharge, patients will be administered validated questionnaires to screen for symptoms of anxiety/depression (HADS), PTSD (IES-r), cognitive dysfunction (MOCA-blind), as well as evaluation of health status (EQ-5D). Six months post ICU discharge, patients will again be contacted and repeat the assessment with above questionnaires. Scores on the questionnaires will be compared between the groups at the two times points. Patient demographic data will also be obtained and assessed to contextualize study findings.
BACKGROUND: The Guatemalan Foundation for Children with Kidney Diseases collaborated with Bridge of Life, a not-for-profit charitable organization, to establish a vascular access program. We reviewed our experience with graded surgical responsibility and structured didactic training, creating arteriovenous fistulas (AVF) for Guatemalan children.
METHODS: Pediatric vascular access missions were completed from 2015 to 2023 and analyzed retrospectively. Follow-up was completed by the Guatemalan pediatric surgeons, nephrologists, and nursing staff. AVF patency and patient survival were evaluated by Kaplan-Meier life-table analysis with univariate and multivariable association between patient demographic variables by Cox proportional hazards models.
RESULTS: Among a total of 153 vascular access operations, there were 139 new patient procedures, forming the study group for this review. The mean age was 13.6 years, 42.6% were female, and the mean BMI was 17.3. Radial or ulnar artery-based direct AVFs were established in 100 patients (71.9%) and ten of the 25 transposition procedures. Brachial artery inflow was required in 29 direct AVFs (20.9%). Two patients underwent femoral vein transpositions. Access-related distal ischemia was not encountered. Seven of the AVF patients later required access banding for arm edema; all had previous dialysis catheters (mean = 9, range 4-12). Primary and cumulative patency rates were 84% and 86% at 12 months and 64% and 81% at 24 months, respectively. The median follow-up was 12 months. Overall patient survival was 84% and 67% at 12 and 24 months, respectively. There were no deaths related to AVF access.
CONCLUSIONS: Safe and functional AVFs were established in a teaching environment within a Guatemalan comprehensive pediatric nephrology center.
Oral epithelial dysplasia is a histologically diagnosed potentially premalignant disorder of the oral mucosa, which carries a risk of malignant transformation to squamous cell carcinoma. The diagnosis and grading of oral epithelial dysplasia is challenging, with cases often referred to specialist oral and maxillofacial pathology centres for second opinion. Even still there is poor inter-examiner and intra-examiner agreement in a diagnosis. There are a total of 28 features of oral epithelial dysplasia listed in the 5th edition of World Health Organization classification of tumours of the head and neck. Each of these features is poorly defined and subjective in its interpretation. Moreover, how these features contribute to dysplasia grading and risk stratification is even less well defined. This article discusses each of the features of oral epithelial dysplasia with examples and provides an overview of the common mimics, including the normal histological features of the oral mucosa which may mimic atypia. This article also highlights the paucity of evidence defining these features while offering suggested definitions. Ideally, these definitions will be refined, and the most important features identified to simplify the diagnosis of oral epithelial dysplasia. Digital whole slide images of the figures in this paper can be found at: https://www.pathogenesis.co.uk/r/demystifying-dysplasia-histology-dataset.
OBJECTIVE: Post-stroke fatigue (PSF) is a common condition among stroke survivors. However, evidence supporting the effective clinical management of PSF is insufficient. Our objectives were to examine the clinical practices of physiotherapists for the management of PSF and evaluate their clinical knowledge and confidence in managing PSF.
SUBJECTS AND METHODS: We conducted a cross-sectional study using an online survey of the sociodemographic profiles of participating physiotherapists, their current clinical practices, clinical knowledge, confidence in their clinical management of PSF, and the types and intensity of the exercises used in the management of PSF.
RESULTS: A total of 160 physiotherapists completed the survey: 86 (53.8%) were women, 148 (92.5%) were Saudi nationals, 126 (78.7%) were employed by the Ministry of Health, and 34 (21.3%) worked in the private sector. The majority (60%) of physiotherapists did not routinely assess their patients for the presence of fatigue. Likewise, 93 (58.1%) did not provide any PSF-related educational material to their patients; however, 67 (41.9%) did provide these materials. The preferred exercises of the physiotherapists for their patients were bed and chair exercises (59.5%), followed by functional training (51.4%), and resistance training (23.1%).
CONCLUSIONS: Our results suggest that while physiotherapists practicing in Saudi Arabia have a sound theoretical understanding of PSF management, their knowledge does not necessarily translate into practice. Interventions used to treat PSF include bed and chair exercises, functional training, and resistance training.
A method of manufacturing a stabilized, essentially sodium free, granular aspirin compound mixed with a granular potassium bicarbonate compound comprising the steps of determining a desirable dose size of such aspirin compound which is to be packaged. Weighing out an amount of granular aspirin based on the dose size determined. Placing an amount of such granular potassium bicarbonate compound into a container which is uniformly distributed over a bottom surface of such container to a predetermined depth. Placing such container into a heat treating apparatus. Heat treating the granular potassium bicarbonate compound at a temperature which is at least sufficient to convert an outer surface layer of such granular potassium bicarbonate compound to potassium carbonate and for a time which is at least sufficient to ensure that essentially all of such outer surface layer of the granular potassium bicarbonate compound is converted to such potassium carbonate. Weighing out an amount of such heat treated granular potassium bicarbonate compound based on the dose size determined. Placing the granular aspirin into a package and, thereafter, placing such heat treated granular potassium bicarbonate compound into such package thereby forming the stabilized, essentially sodium free, granular aspirin compound mixed with a granular potassium bicarbonate compound.
Investigators enrolled 598 patients who were sent to thoracic postoperative intensive care unit (ICU) ward right after surgery from August 8 to September 12 of 2017 and those patients stayed in ICU for at least 24 hours. Excluded non-lung surgery there were 581 lung surgery cases. Investigators adopted the Caprini VTE risk assessment model from Boston Medical Center (BMC) in United States of America (USA). According to different risk level, participants received different thromboprophylaxis strategies. Early ambulation alone was for patients at low risk (Caprini 0-4), early chemoprophylaxis plus early ambulation was for patients at moderate (Caprini 5-8) or high risk (Caprini ≥9). Early chemoprophylaxis means low-molecular weight heparin (LMWH) 3075 IU (WHO Units) injection subcutaneously one time a day no later than 24 hours after surgery. Early ambulation means activity out of bed no later than 24 hours after surgery. Thromboprophylaxis contraindication included chest tube drainage more than 500 ml or major bleeding during operation or surgeons refusing to use thromboprophylaxis because they thought that patients would benefit more from not performing early ambulation or chemoprophylaxis. Some patients received chemoprophylaxis after they moved back to regular ward out of ICU which was called late chemoprophylaxis which means more than 24 hours after surgery. All chemoprophylaxis were used only during hospitalization. When participants were discharged, no extended treatment prescribed. However, they were followed up twice on 30 days and 60 days after surgery by phone call.